L.F. van der Voort

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

Robert C. Axtell, Brigit A. de Jong, Katia Boniface et al. · Nature Medicine · 2010 · 530 citations · Full text

Cells Determine Efficacy, Autoimmune Disease, Adaptive Immune System +13

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

Lisa G. M. van Baarsen, Saskia Vosslamber, Marianne Tijssen et al. · PLoS ONE · 2008 · 114 citations · Full text

Clinical Effect of Neutralizing Antibodies to Interferon Beta That Persist Long After Cessation of Therapy for Multiple Sclerosis

L.F. van der Voort · Archives of Neurology · 2010 · 36 citations

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis

Saskia Vosslamber, L.F. van der Voort, I.J. van den Elskamp et al. · Genes and Immunity · 2011 · 34 citations

Autoimmune Disease, Interferonβ Therapy, Medicine +11

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

L.F. van der Voort, Anke Vennegoor, Allerdien Visser et al. · Neurology · 2010 · 34 citations